HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture

Toxicology and Applied Pharmacology

Volumn 145, Issue 1, 1997, Pages 99-110

  Flint, Oliver P ^a   Masters, Barbara A ^a   Gregg, Richard E ^b   Durham, Stephen K ^b  

^a BRISTOL MYERS SQUIBB COMPANY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESOL; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; ISOPRENYLATION; MORPHOLOGY; MYOPATHY; NONHUMAN; PROTEIN SYNTHESIS; RAT; SKELETAL MUSCLE;

ANIMALIA; MAMMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0031193851     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8174     Document Type: Article

References (41)

1. Bifulco M., Laezza C., Aloj S. M., Garbi C. Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J. Cell Physiol. 155:1993;340-348.
2. Bizzaro N., Bagolin E., Milani L., Cereser C., Finco B. Massive rhabdomyolysis and simvastatin. Clin. Chem. 38:1992;1504.
3. Chariot P., Abadia R., Agnus D., Danan C., Charpentier C., Gherardi R. K. Simvastatin-induced rhabdomyolysis followed by a melas syndrome. Am. J. Med. 94:1993;109-110.
4. Chrysanthopoulos C., Kounis N. Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine. BMJ. 304:1992;1225.
5. Churallah A., De Girolami U., Freeman R., Federman M. Lovastatin/gemfibrozil myopathy: A clinical, histochemical, and ultrastructural study. Eur. Neurol. 32:1992;293-296.
6. Cox A. D., Hisaka M. M., Buss J. E., Der C. J. Specific isoprenoid modification is required for function of normal, but not oncogenic, ras protein. Mol. Cell. Biol. 12:1992;2606-2615.
7. Crowell P. L., Chang R. R., Ren Z., Elson C. E., Gould M. N. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J. Biol. Chem. 266:1991;17679-17685.
8. Danesi R., McLellan C. A., Myers C. E. Specific labeling of isoprenylated proteins: Application to study inhibitors of the post-translational farnesylation and geranylgeranylation. Biochem. Biophys. Res. Commun. 206:1995;637-643.
9. De Alava E., Sola J. J., Lozano M. D., Pardo-Mindan F. J. Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants. Nephron. 66:1994;242-243.
10. East C., Alivizatos P. A., Grundy S. M., Jones P. H., Farmer J. A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N. Engl. J. Med. 318:1988;47-48.
11. Epstein W. W., Lever D., Leining L. M., Bruenger E., Rilling H. C. Quantitation of prenylcysteines by a selective cleavage reaction. Proc. Natl. Acad. Sci. USA. 88:1991;9668-9670.
12. Flint O. P., Masters B. A., Gregg R., Durham S. K. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicityin vitro. Toxicol. Appl. Pharmacol. 145:1996;91-98.
13. Goldstein J. L., Brown M. S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
14. 2+. Cell. Signal. 6:1994;735-742.
15. 2. Br. J. Cancer. 69:1994;1015-1020.
16. Laaksonen R., Ojala J. P., Tikkanen M. J., Himberg J. J. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 46:1994;313-317.
17. Laaksonen R., Jokelainen K., Sahi T., Tikkanen M. J., Himberg J. J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Pharmacol. Ther. 57:1995;62-66.
18. Maher V. M. G., Pappu A., Illingworth D. R., Thompson G. R. Plasma mevalonate response in lovastatin-related myotherapy. Lancet. 2:1989;1098.
19. Maltese W. A., Sheridan K. M. Isoprenylated proteins in cultured cells: Subcellular distribution and changes related to altered morphology and growth arrest induced by mevalonate deprivation. J. Cell Physiol. 133:1987;471-481.
20. Maltese W. A. Post translational modification of proteins by isoprenoids in mammalian cells. FASEB J. 4:1990;3319-3328.
21. Manne V., Yan N., Carboni J. M., Tuomari A. V., Ricca C. S., Brown J. G., Andahazy M. L., Schmidt R. J., Patel D., Zahler R. Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells. Oncogene. 10:1995;1765-1779.
22. Manoukian A. A., Bhagavan N. V., Hayashi T., Nestor T. A., Rios C., Scottolini A. G. Rhabdomyolysis secondary to lovastatin therapy. Clin. Chem. 36:1990;2145-2147.
23. Masters B. A., Palmoski M. J., Flint O. P., Gregg R. E., Wang-Iverson D., Durham S. K. In vitro. Toxicol. Appl. Pharmacol. 131:1995;163-174.
24. Metz S. A., Rabaglia M. E., Stock J. B., Kowlurec A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP binding proteins. Biochem. J. 295:1993;31-40.
25. Nagase T., Kawata S., Tamura S., Masuda Y., Inui Y., Yamasaki E., Ishiguro H., Ito T., Matsuzawa Y. Inhibition of cell growth of human hepatoma cell line (HepG2) by a farnesyl protein transferase inhibitor: A preferential suppression of Ras farnesylation. Int. J. Cancer. 65:1996;620-626.
26. O'Donnell M. P., Kasiske B. L., Kim Y., Atluru D., Keane W. F. The mevalonate pathway: Importance in mesangial cell biology and glomerular disease. Miner Electrolyte Metab. 19:1993;173-179.
27. O'Donnell M. P., Kasiske B. L., Kim Y., Atluru D., Keane W. F. Lovastatin inhibits proliferation of rat mesangial cells. J. Clin. Invest. 91:1993;83-87.
28. Pierce L. R., Wysowski D. K., Gross T. P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy [see comments]. JAMA. 264:1990;71-75.
29. Plumb J. Culture of specific cell types. Culture of Animal Cells. 1987;Alan R. Liss, New York. p. 271-272.
30. Raimondeau J., Le Marc H., Chevallier J. C., Bouhour J. B. Biological myolysis during combined fenofibrate and pravastatin treatment. Presse Med. 21:1992;663-664.
31. Repko E. M., Maltese W. A. Post-translational isoprenylation of cellular proteins is altered in response to mevalonate availability. J. Biol. Chem. 264:1989;9945-9952.
32. Rilling H. C., Bruenger E., Leining L. M., Buss J. E., Epstein W. W. Differential prenylation of proteins as a function of mevalonate concentration in CHO cells. Arch. Biochem. Biophys. 301:1993;210-215.
33. Schalke B. B., Schmidt B., Toyka K., Hartung H. Pravastatin-associated inflammatory myopathy. N. Engl. J. Med. 327:1992;649-650.
34. Schulz S., Buhling F., Ansorge S. Prenylated proteins and lymphocyte proliferation: Inhibition by d-limonene related monoterpenes. Eur. J. Immunol. 24:1994;301-307.
35. Sepp-Lorenzino L., Azrolan N., Coleman P. S. Cellular distribution of cholesterogenesis-linked, phospho-isoprenylated proteins in proliferating cells. FEBS Lett. 245:1989;110-116.
36. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
37. Tobert J. A. Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol. 62:1988;28J-34J.
38. Tobert J. A., Shear C. L., Chremos A. N., Mantell G. E. Clinical experience with lovastatin. Am. J. Cardiol. 65:1990;23F-26F.
39. Walravens P. A., Greene C., Frefman F. E. Lovastatin isoprenes, and myopathy. Lancet. 1989;1097-1098.
40. Xu X. Q., McGuire T. F., Blaskovich M. A., Sebti S. M., Romero G. Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts. Arch. Biochem. Biophys. 326:1996;233-237.
41. Yaffe D. Preparation of primary cultures: Rat skeletal muscle cells. Kruse P. F., Patterson M. K. Tissue Culture Methods and Applications. 1973;106-114 Academic Press, New York.